Agios Pharm Stock Performance
| AGIO Stock | USD 39.65 0.91 2.24% |
On a scale of 0 to 100, Agios Pharm holds a performance score of 16. The firm shows a Beta (market volatility) of -0.77, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Agios Pharm are expected to decrease at a much lower rate. During the bear market, Agios Pharm is likely to outperform the market. Please check Agios Pharm's semi variance, day typical price, and the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether Agios Pharm's price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Agios Pharm are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady forward indicators, Agios Pharm displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 88.2 M | |
| Total Cashflows From Investing Activities | 363.4 M |
Agios Pharm Relative Risk vs. Return Landscape
If you would invest 2,962 in Agios Pharm on April 26, 2025 and sell it today you would earn a total of 1,003 from holding Agios Pharm or generate 33.86% return on investment over 90 days. Agios Pharm is currently generating 0.5% in daily expected returns and assumes 2.4171% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Agios, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Agios Pharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Agios Pharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Agios Pharm, and traders can use it to determine the average amount a Agios Pharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2068
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AGIO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.42 actual daily | 21 79% of assets are more volatile |
Expected Return
| 0.5 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average Agios Pharm is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Agios Pharm by adding it to a well-diversified portfolio.
Agios Pharm Fundamentals Growth
Agios Stock prices reflect investors' perceptions of the future prospects and financial health of Agios Pharm, and Agios Pharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Agios Stock performance.
| Return On Equity | 0.6 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | 17.98 % | ||||
| Operating Margin | (12.22) % | ||||
| Current Valuation | 1.51 B | ||||
| Shares Outstanding | 57.92 M | ||||
| Price To Earning | 1.26 X | ||||
| Price To Book | 1.60 X | ||||
| Price To Sales | 62.00 X | ||||
| Revenue | 36.5 M | ||||
| EBITDA | (425.74 M) | ||||
| Cash And Equivalents | 819.31 M | ||||
| Cash Per Share | 14.95 X | ||||
| Total Debt | 56.99 M | ||||
| Debt To Equity | 0.08 % | ||||
| Book Value Per Share | 25.33 X | ||||
| Cash Flow From Operations | (389.84 M) | ||||
| Earnings Per Share | 11.54 X | ||||
| Total Asset | 1.66 B | ||||
| Retained Earnings | (148.92 M) | ||||
| Current Asset | 337.33 M | ||||
| Current Liabilities | 52.89 M | ||||
About Agios Pharm Performance
By examining Agios Pharm's fundamental ratios, stakeholders can obtain critical insights into Agios Pharm's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Agios Pharm is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Agios Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 0 people.Things to note about Agios Pharm performance evaluation
Checking the ongoing alerts about Agios Pharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Agios Pharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Agios Pharm currently holds about 819.31 M in cash with (389.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.95. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Agios Pharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Agios Pharm's stock is overvalued or undervalued compared to its peers.
- Examining Agios Pharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Agios Pharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Agios Pharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Agios Pharm's stock. These opinions can provide insight into Agios Pharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.